首页 > 最新文献

Clinical Immunology Communications最新文献

英文 中文
Anti-Saccharomyces cerevisiae (ASCA) in patients with severe obesity undergoing bariatric surgery: 12-month follow-up. 对接受减肥手术的重度肥胖症患者进行抗酵母菌(ASCA)治疗:12 个月随访。
Pub Date : 2024-02-09 DOI: 10.1016/j.clicom.2024.02.001
Emerita Quintina de Andrade Moura , Bruno Fonseca Nunes , Letícia de Oliveira Souza Bratti , Fabíola Branco Filippin Monteiro

Severe obesity is linked to a low-grade inflammatory process due to enlarged adipose tissue, resulting in elevated pro-inflammatory cytokines. Bariatric surgery induces anatomical changes, causing intestinal inflammation marked by anti-Saccharomyces cerevisiae (ASCA) antibodies. This study aimed to assess ASCA IgG/IgA levels preoperatively and 12 months post-surgery, correlating them with systemic inflammation markers (IL-6, CRP, MCP-1). Participants (BMI > 35 kg/m2) were recruited in South Brazil. Severe obesity individuals showed elevated IL-6 (p = 0.002), CRP (p<0.0001), and MCP-1 (p<0.0001) compared to lean controls. ASCA IgA was significantly higher in severe obesity (p = 0.0019). Post-surgery, ASCA IgG/IgA significantly decreased (p = 0.0046 and p<0.0001), along with IL-6, MCP-1, and CRP, confirming weight loss and reduced inflammation. Hypertrophic adipose tissue, producing pro-inflammatory cytokines, associates with increased intestinal inflammation. Bariatric surgery-induced anatomical changes contribute to long-term weight loss and reduced systemic and intestinal inflammation.

严重肥胖与低度炎症过程有关,因为脂肪组织增大,导致促炎细胞因子升高。减肥手术会引起解剖学上的变化,导致肠道炎症,并以抗酵母菌(ASCA)抗体为标志。本研究旨在评估术前和术后 12 个月的 ASCA IgG/IgA 水平,并将其与全身炎症指标(IL-6、CRP、MCP-1)相关联。我们在南巴西招募了一些参与者(体重指数为 35 kg/m2)。与瘦对照组相比,重度肥胖者的 IL-6 (p = 0.002)、CRP (p<0.0001) 和 MCP-1 (p<0.0001) 均有所升高。严重肥胖者的 ASCA IgA 明显更高(p = 0.0019)。手术后,ASCA IgG/IgA 明显降低(p = 0.0046 和 p<0.0001),IL-6、MCP-1 和 CRP 也明显降低,证实了体重减轻和炎症减轻。肥胖的脂肪组织会产生促炎细胞因子,与肠道炎症的增加有关。减肥手术引起的解剖学变化有助于长期减轻体重,减少全身和肠道炎症。
{"title":"Anti-Saccharomyces cerevisiae (ASCA) in patients with severe obesity undergoing bariatric surgery: 12-month follow-up.","authors":"Emerita Quintina de Andrade Moura ,&nbsp;Bruno Fonseca Nunes ,&nbsp;Letícia de Oliveira Souza Bratti ,&nbsp;Fabíola Branco Filippin Monteiro","doi":"10.1016/j.clicom.2024.02.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2024.02.001","url":null,"abstract":"<div><p>Severe obesity is linked to a low-grade inflammatory process due to enlarged adipose tissue, resulting in elevated pro-inflammatory cytokines. Bariatric surgery induces anatomical changes, causing intestinal inflammation marked by anti-Saccharomyces cerevisiae (ASCA) antibodies. This study aimed to assess ASCA IgG/IgA levels preoperatively and 12 months post-surgery, correlating them with systemic inflammation markers (IL-6, CRP, MCP-1). Participants (BMI &gt; 35 kg/m<sup>2</sup>) were recruited in South Brazil. Severe obesity individuals showed elevated IL-6 (<em>p</em> = 0.002), CRP (<em>p</em>&lt;0.0001), and MCP-1 (<em>p</em>&lt;0.0001) compared to lean controls. ASCA IgA was significantly higher in severe obesity (<em>p</em> = 0.0019). Post-surgery, ASCA IgG/IgA significantly decreased (<em>p</em> = 0.0046 and <em>p</em>&lt;0.0001), along with IL-6, MCP-1, and CRP, confirming weight loss and reduced inflammation. Hypertrophic adipose tissue, producing pro-inflammatory cytokines, associates with increased intestinal inflammation. Bariatric surgery-induced anatomical changes contribute to long-term weight loss and reduced systemic and intestinal inflammation.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613424000027/pdfft?md5=c057dcb1c1af28dc7e6c2a63f5eb5bcd&pid=1-s2.0-S2772613424000027-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139725789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating length of immune response to SARS-CoV2 vaccine: A cohort review of spike protein antibody titer after vaccination 评估对 SARS-CoV2 疫苗免疫反应的持续时间:疫苗接种后尖峰蛋白抗体效价队列回顾
Pub Date : 2024-01-28 DOI: 10.1016/j.clicom.2024.01.001
Zein Kattih , Jonathan Moore , Dimitre G. Stefanov , Priyanka Makkar , Viera Lakticova

Background

The SARS-CoV2 pandemic required rapid development and expedited evaluation of vaccine efficacy. Initial evidence suggested waning immune response to SARS-CoV2 vaccination steadily over the first six months. This study evaluated duration of immunity in vaccinated patients at a single tertiary center in New York City during the pandemic.

Methods

We conducted a retrospective review of adult vaccinated patients admitted over a period of 3 months during the SARS-CoV2-Omicron variant and evaluated their immune response using the spike protein antibody titer. A total of 2476 patients were screened, and 1875 patients were included in the study. Secondary analysis of a cohort of patients with COVID-19 disease was also performed.

Results

Spike protein antibody was positive in 99 % of patients. Most patients received two doses of the Pfizer (42 %) or the Moderna (27 %) vaccines. There was a negative correlation between months since vaccination and spike protein antibody titer (Spearman's rank correlation –0.094, p <0.0001). Subgroup analysis of those who had received at least two doses of a vaccine series revealed similar negative correlations for both Pfizer (Spearman's rank correlation –0.14, p <0.0001) and Moderna vaccines (Spearman's rank correlation –0.11, p = 0.0043). Secondary analysis of patients admitted with a diagnosis of COVID-19 infection did not demonstrate any statistically significant difference in titer results over time.

Conclusions

Our study of patients admitted to a tertiary care center across a diverse patient population demonstrated that patients who were vaccinated against SARS-COV2 had a robust response in their spike protein antibody titer which was maintained well beyond six months after vaccination.

背景SARS-CoV2 大流行要求快速开发疫苗并加快对疫苗功效的评估。初步证据表明,在最初的六个月中,接种 SARS-CoV2 疫苗后的免疫反应会逐渐减弱。我们对 SARS-CoV2-Omicron 变异期间 3 个月内收治的成年疫苗接种患者进行了回顾性审查,并使用尖峰蛋白抗体滴度评估了他们的免疫反应。共有 2476 名患者接受了筛查,其中 1875 名患者被纳入研究。结果99%的患者尖峰蛋白抗体呈阳性。大多数患者接种了两剂辉瑞疫苗(42%)或莫德纳疫苗(27%)。接种疫苗后的月数与尖峰蛋白抗体滴度呈负相关(Spearman's rank correlation -0.094, p <0.0001)。对至少接种过两剂疫苗的患者进行分组分析后发现,辉瑞疫苗(Spearman秩相关-0.14,p <0.0001)和Moderna疫苗(Spearman秩相关-0.11,p = 0.0043)也存在类似的负相关。对诊断为 COVID-19 感染的入院患者进行的二次分析表明,随着时间的推移,滴度结果没有任何统计学意义上的显著差异。
{"title":"Evaluating length of immune response to SARS-CoV2 vaccine: A cohort review of spike protein antibody titer after vaccination","authors":"Zein Kattih ,&nbsp;Jonathan Moore ,&nbsp;Dimitre G. Stefanov ,&nbsp;Priyanka Makkar ,&nbsp;Viera Lakticova","doi":"10.1016/j.clicom.2024.01.001","DOIUrl":"10.1016/j.clicom.2024.01.001","url":null,"abstract":"<div><h3>Background</h3><p>The SARS-CoV2 pandemic required rapid development and expedited evaluation of vaccine efficacy. Initial evidence suggested waning immune response to SARS-CoV2 vaccination steadily over the first six months. This study evaluated duration of immunity in vaccinated patients at a single tertiary center in New York City during the pandemic.</p></div><div><h3>Methods</h3><p>We conducted a retrospective review of adult vaccinated patients admitted over a period of 3 months during the SARS-CoV2-Omicron variant and evaluated their immune response using the spike protein antibody titer. A total of 2476 patients were screened, and 1875 patients were included in the study. Secondary analysis of a cohort of patients with COVID-19 disease was also performed.</p></div><div><h3>Results</h3><p>Spike protein antibody was positive in 99 % of patients. Most patients received two doses of the Pfizer (42 %) or the Moderna (27 %) vaccines. There was a negative correlation between months since vaccination and spike protein antibody titer (Spearman's rank correlation –0.094, <em>p</em> &lt;0.0001). Subgroup analysis of those who had received at least two doses of a vaccine series revealed similar negative correlations for both Pfizer (Spearman's rank correlation –0.14, <em>p</em> &lt;0.0001) and Moderna vaccines (Spearman's rank correlation –0.11, <em>p</em> = 0.0043). Secondary analysis of patients admitted with a diagnosis of COVID-19 infection did not demonstrate any statistically significant difference in titer results over time.</p></div><div><h3>Conclusions</h3><p>Our study of patients admitted to a tertiary care center across a diverse patient population demonstrated that patients who were vaccinated against SARS-COV2 had a robust response in their spike protein antibody titer which was maintained well beyond six months after vaccination.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613424000015/pdfft?md5=f4633bf721f316ced2394d5c29235569&pid=1-s2.0-S2772613424000015-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139633410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune microenvironment and progress in immunotherapy of cholangiocarcinoma 胆管癌免疫微环境及免疫治疗进展
Pub Date : 2023-11-29 DOI: 10.1016/j.clicom.2023.11.002
Xinyu Shao

Cholangiocarcinoma (CCA) is a group of malignant digestive system tumors with a poor overall prognosis. Late diagnosis and limited treatment are the main problems of CCA. Immunotherapy is a promising method to improve the prognosis, but the immunosuppression of CCA tumor microenvironment hinders the development and implementation of immunotherapy. Therefore, a full understanding of the complex components of CCA and its tumor immune microenvironment (TiME) can better understand the pathogenesis and drug resistance mechanism of CCA and contribute to the discovery of new immunotherapy targets. This article reviews the TiME related research on CCA, comprehensively discusses the components of the immune microenvironment of cholangiocarcinoma, and introduces the research progress of immunotherapy and immune combination therapy for CCA.

胆管癌(CCA)是一组整体预后较差的消化系统恶性肿瘤。诊断晚、治疗有限是CCA的主要问题。免疫治疗是一种很有希望改善预后的方法,但CCA肿瘤微环境的免疫抑制阻碍了免疫治疗的发展和实施。因此,充分了解CCA及其肿瘤免疫微环境(TiME)的复杂组成,可以更好地了解CCA的发病机制和耐药机制,有助于发现新的免疫治疗靶点。本文综述了近年来胆管癌免疫微环境的相关研究,全面探讨了胆管癌免疫微环境的组成,并介绍了胆管癌免疫治疗及免疫联合治疗的研究进展。
{"title":"Immune microenvironment and progress in immunotherapy of cholangiocarcinoma","authors":"Xinyu Shao","doi":"10.1016/j.clicom.2023.11.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.11.002","url":null,"abstract":"<div><p>Cholangiocarcinoma (CCA) is a group of malignant digestive system tumors with a poor overall prognosis. Late diagnosis and limited treatment are the main problems of CCA. Immunotherapy is a promising method to improve the prognosis, but the immunosuppression of CCA tumor microenvironment hinders the development and implementation of immunotherapy. Therefore, a full understanding of the complex components of CCA and its tumor immune microenvironment (TiME) can better understand the pathogenesis and drug resistance mechanism of CCA and contribute to the discovery of new immunotherapy targets. This article reviews the TiME related research on CCA, comprehensively discusses the components of the immune microenvironment of cholangiocarcinoma, and introduces the research progress of immunotherapy and immune combination therapy for CCA.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277261342300029X/pdfft?md5=96a4cfb37b3b9075b3279e4257bd499c&pid=1-s2.0-S277261342300029X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138475163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TBE-antibody titer study: Is a booster already necessary after 5 years? tbe抗体滴度研究:5年后是否需要加强?
Pub Date : 2023-11-09 DOI: 10.1016/j.clicom.2023.11.001
Katharina Mahlfleisch, Susanne Pauschenwein, Thomas Pekar

As long as there is only symptomatic treatment against thick-borne encephalitis (TBE) available, vaccination is considered the only prevention against infection.

The national vaccination recommendations prescribe a booster vaccination every 5 years after a basic vaccination has been carried out. This study deals with the question if antibodies in sufficient concentration exist or not when the last immunization had been five years ago.

The TBE titer was determined in 168 subjects using indirect ELISA and the vaccination history was collected.

The results show that 97.3 % of the participants have a sufficient titer 5 years after the last booster vaccination. The time period since the last booster and the type of the vaccine influence the antibody level the most. In conclusion, it was found that by controlling the titer, it is possible to postpone a booster vaccination, if the immunization is still sufficient.

只要对厚源性脑炎(TBE)只有对症治疗,疫苗接种就被认为是预防感染的唯一方法。国家疫苗接种建议规定,在进行基本疫苗接种后,每5年进行一次加强疫苗接种。本研究涉及的问题,是否有足够浓度的抗体存在时,最后一次免疫是在五年前。采用间接ELISA法测定168例患者的TBE滴度,并收集疫苗接种史。结果显示,97.3%的参与者在最后一次加强疫苗接种5年后有足够的滴度。自最后一次加强疫苗以来的时间周期和疫苗类型对抗体水平影响最大。总之,通过控制滴度,如果免疫仍然足够,可以推迟加强疫苗接种。
{"title":"TBE-antibody titer study: Is a booster already necessary after 5 years?","authors":"Katharina Mahlfleisch,&nbsp;Susanne Pauschenwein,&nbsp;Thomas Pekar","doi":"10.1016/j.clicom.2023.11.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.11.001","url":null,"abstract":"<div><p>As long as there is only symptomatic treatment against thick-borne encephalitis (TBE) available, vaccination is considered the only prevention against infection.</p><p>The national vaccination recommendations prescribe a booster vaccination every 5 years after a basic vaccination has been carried out. This study deals with the question if antibodies in sufficient concentration exist or not when the last immunization had been five years ago.</p><p>The TBE titer was determined in 168 subjects using indirect ELISA and the vaccination history was collected.</p><p>The results show that 97.3 % of the participants have a sufficient titer 5 years after the last booster vaccination. The time period since the last booster and the type of the vaccine influence the antibody level the most. In conclusion, it was found that by controlling the titer, it is possible to postpone a booster vaccination, if the immunization is still sufficient.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613423000288/pdfft?md5=b6c5501b117cf506020a828a1da6f044&pid=1-s2.0-S2772613423000288-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92116947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges in the diagnosis and management of SLE in India 印度SLE诊断和管理的挑战
Pub Date : 2023-10-18 DOI: 10.1016/j.clicom.2023.10.001
Rudrarpan Chatterjee, Amita Aggarwal

Management of Systemic lupus erythematosus is challenging due to its varied manifestations, relapses and problems associated with immunosuppressive therapy. This challenge is compounded in resource limited countries due to additional factors such as poor access to health care, limited income, out of pocket expenses for medical care and lack of financial independence of women. In the current review some of these issues have been highlighted in context of India, the most populous country of the world with current annual per capita income of around 2000 dollars.

系统性红斑狼疮的管理是具有挑战性的,因为它的各种表现,复发和免疫抑制治疗相关的问题。在资源有限的国家,由于难以获得保健服务、收入有限、自费支付医疗费用以及妇女缺乏经济独立等其他因素,这一挑战更加严峻。在目前的审查中,其中一些问题在印度的背景下得到强调,印度是世界上人口最多的国家,目前人均年收入约为2000美元。
{"title":"Challenges in the diagnosis and management of SLE in India","authors":"Rudrarpan Chatterjee,&nbsp;Amita Aggarwal","doi":"10.1016/j.clicom.2023.10.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.10.001","url":null,"abstract":"<div><p>Management of Systemic lupus erythematosus is challenging due to its varied manifestations, relapses and problems associated with immunosuppressive therapy. This challenge is compounded in resource limited countries due to additional factors such as poor access to health care, limited income, out of pocket expenses for medical care and lack of financial independence of women. In the current review some of these issues have been highlighted in context of India, the most populous country of the world with current annual per capita income of around 2000 dollars.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613423000276/pdfft?md5=29c6a1975841e985cf4103be77469c87&pid=1-s2.0-S2772613423000276-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92149049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic lupus erythematosus in Latin America: Outcomes and therapeutic challenges 拉丁美洲的系统性红斑狼疮:结果和治疗挑战
Pub Date : 2023-10-17 DOI: 10.1016/j.clicom.2023.10.002
Manuel F. Ugarte-Gil , Graciela S. Alarcón

Systemic lupus erythematosus (SLE) affects more severely non-White populations, which is also the case in Latin America; this is the result of a combination of genetic and non-genetic factors. Among the non-genetic factors, a limited income and a low educational level impact negatively on the course and outcome of the disease; in addition, lack of access to healthcare services deprives patients from the opportunity of being managed by specialists, making the availability of the newest drugs practically impossible. Taking together, these factors reduce the probability of patients achieving good outcomes, like remission, less damage accrual, a better survival and a better health-related quality of life, among others. Several strategies have been proposed to reduce these disparities, including peer education, educational activities for patients and primary care physicians, improving healthcare networks and generating cost-effectiveness analyses.

系统性红斑狼疮(SLE)对非白人人群的影响更为严重,拉丁美洲也是如此;这是遗传和非遗传因素共同作用的结果。在非遗传因素中,收入有限和教育水平低对疾病的进程和结果产生负面影响;此外,缺乏医疗服务使患者失去了由专家管理的机会,使最新药物的供应几乎不可能。综合来看,这些因素降低了患者获得良好结果的概率,如病情缓解、损伤减少、生存率提高和健康相关生活质量提高等。已经提出了一些减少这些差异的战略,包括同伴教育、为患者和初级保健医生开展教育活动、改善医疗保健网络和进行成本效益分析。
{"title":"Systemic lupus erythematosus in Latin America: Outcomes and therapeutic challenges","authors":"Manuel F. Ugarte-Gil ,&nbsp;Graciela S. Alarcón","doi":"10.1016/j.clicom.2023.10.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.10.002","url":null,"abstract":"<div><p>Systemic lupus erythematosus (SLE) affects more severely non-White populations, which is also the case in Latin America; this is the result of a combination of genetic and non-genetic factors. Among the non-genetic factors, a limited income and a low educational level impact negatively on the course and outcome of the disease; in addition, lack of access to healthcare services deprives patients from the opportunity of being managed by specialists, making the availability of the newest drugs practically impossible. Taking together, these factors reduce the probability of patients achieving good outcomes, like remission, less damage accrual, a better survival and a better health-related quality of life, among others. Several strategies have been proposed to reduce these disparities, including peer education, educational activities for patients and primary care physicians, improving healthcare networks and generating cost-effectiveness analyses.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49727533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disseminated tuberculosis, CMV viraemia & haemophagocytic-lymphohistiocystosis syndrome in an adult patient with anti- IFNγ autoantibodies – case report and brief review 成人抗IFNγ自身抗体患者的弥散性结核、巨细胞病毒血症和噬血细胞淋巴组织囊积综合征——病例报告和简要回顾
Pub Date : 2023-09-01 DOI: 10.1016/j.clicom.2023.08.001
G.I. Butel-Simoes , C. Kiss , K. Kong , L.B. Rosen , L.M. Hosking , S. Barnes , G.A. Jenkin , S. Megaloudis , B. Kumar , S.M. Holland , S. Ojaimi

We report a case of an adult female with disseminated tuberculosis, cytomegalovirus viraemia and haemophagocytic-lymphohistiocystosis syndrome associated with neutralizing anti- interferon gamma (IFNγ) autoantibodies demonstrated by absent IFNγ stimulated STAT1 phosphorylation in the presence of patient sera. A brief review of immunodeficiency caused by anti-IFNγ autoantibodies is also described.

我们报告了一例患有播散性肺结核、巨细胞病毒血症和吞噬细胞性淋巴组织囊肿综合征的成年女性病例,该综合征与中和性抗干扰素γ(IFNγ)自身抗体相关,在患者血清存在的情况下,通过缺乏IFNγ刺激的STAT1磷酸化来证明。还简要介绍了抗IFNγ自身抗体引起的免疫缺陷。
{"title":"Disseminated tuberculosis, CMV viraemia & haemophagocytic-lymphohistiocystosis syndrome in an adult patient with anti- IFNγ autoantibodies – case report and brief review","authors":"G.I. Butel-Simoes ,&nbsp;C. Kiss ,&nbsp;K. Kong ,&nbsp;L.B. Rosen ,&nbsp;L.M. Hosking ,&nbsp;S. Barnes ,&nbsp;G.A. Jenkin ,&nbsp;S. Megaloudis ,&nbsp;B. Kumar ,&nbsp;S.M. Holland ,&nbsp;S. Ojaimi","doi":"10.1016/j.clicom.2023.08.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.08.001","url":null,"abstract":"<div><p>We report a case of an adult female with disseminated tuberculosis, cytomegalovirus viraemia and haemophagocytic-lymphohistiocystosis syndrome associated with neutralizing anti- interferon gamma (IFNγ) autoantibodies demonstrated by absent IFNγ stimulated STAT1 phosphorylation in the presence of patient sera. A brief review of immunodeficiency caused by anti-IFNγ autoantibodies is also described.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49753005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time-series COVID-19 policy outcome analysis of the 50U.S. states 美国50个州COVID-19政策结果的时序分析。州
Pub Date : 2023-08-23 DOI: 10.1016/j.clicom.2023.08.002
Yoshiyasu Takefuji , Junya Toyokura

Goal of health policies is to protect and promote the health of communities. We examined COVID-19 policy outcomes of the 50 US states according to policymaker assumptions over time. With daily cumulative population mortality chosen as an indicator to evaluate and score outcomes of individual health policies, Hawaii had the best score and Arizona has the worst score. Our policy outcome analysis tool could identify and quantify policymakers’ faulty assumptions against COVID-19, and concludes that the more COVID-19 deaths, the greater the economic loss.

卫生政策的目标是保护和促进社区的健康。根据政策制定者的假设,我们研究了美国50个州的新冠肺炎政策结果。选择每日累计人口死亡率作为评估和评分个人卫生政策结果的指标,夏威夷得分最高,亚利桑那得分最差。我们的政策结果分析工具可以识别和量化政策制定者对新冠肺炎的错误假设,并得出结论,新冠肺炎死亡人数越多,经济损失就越大。
{"title":"Time-series COVID-19 policy outcome analysis of the 50U.S. states","authors":"Yoshiyasu Takefuji ,&nbsp;Junya Toyokura","doi":"10.1016/j.clicom.2023.08.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.08.002","url":null,"abstract":"<div><p>Goal of health policies is to protect and promote the health of communities. We examined COVID-19 policy outcomes of the 50 US states according to policymaker assumptions over time. With daily cumulative population mortality chosen as an indicator to evaluate and score outcomes of individual health policies, Hawaii had the best score and Arizona has the worst score. Our policy outcome analysis tool could identify and quantify policymakers’ faulty assumptions against COVID-19, and concludes that the more COVID-19 deaths, the greater the economic loss.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49753029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel approaches that promote lung endothelial and epithelial repair and anti pro inflammatory cytokines could be a future promising agent in the management of ARDS 促进肺内皮和上皮修复和抗促炎细胞因子的新方法可能是未来治疗ARDS的有希望的药物
Pub Date : 2023-07-28 DOI: 10.1016/j.clicom.2023.07.005
Montaser Alrjoob , Alaa Alkhatib , Rana Padappayil , Husam Bader , Doantrang Du , Chandler Patton

The acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in critically ill patients and is defined by the acute onset of noncardiogenic pulmonary edema, hypoxemia, and the need for mechanical ventilation. ARDS occurs most often in the setting of pneumonia, sepsis, aspiration of gastric contents or severe trauma, and is present in ∼10% of all intensive care unit patients worldwide. Pathologic specimens from patients with ARDS most frequently reveal diffuse alveolar damage, and laboratory studies have demonstrated both alveolar epithelial and lung endothelial injury, resulting in accumulation of protein-rich inflammatory edema fluid in the alveolar space. The current therapeutic regimen is comprised of supportive measures such as lung protective ventilation, restrictive fluid management, paralyzing drugs, and prone positioning. Although vast improvements have been made in ARDS-treatment during the last five decades, mortality among patients with severe ARDS remains at an unacceptable rate of 45%.This article reviews the evolution of the currently used definition, established pathophysiological mechanism, highlights the current best clinical practice to treat ARDS, gives a brief outlook on cutting edge trends in ARDS research and closes with an expert opinion on the subject. The ongoing digital revolution will help to individualize ARDS-treatment and will therefore presumably improve survival and quality of life.

急性呼吸窘迫综合征(ARDS)是危重患者呼吸衰竭的常见原因,其定义为急性发作的非心源性肺水肿、低氧血症和需要机械通气。ARDS最常发生在肺炎、败血症、胃内容物抽吸或严重创伤的情况下,全球约10%的重症监护室患者都存在ARDS。ARDS患者的病理标本最常显示弥漫性肺泡损伤,实验室研究表明肺泡上皮和肺内皮损伤,导致肺泡间隙积聚富含蛋白质的炎性水肿液。目前的治疗方案包括支持性措施,如肺部保护性通气、限制性液体管理、麻痹药物和俯卧位。尽管在过去的五十年里,ARDS的治疗取得了巨大的进步,但严重ARDS患者的死亡率仍保持在45%的不可接受的水平。本文综述了目前使用的定义、已建立的病理生理机制的演变,强调了目前治疗ARDS的最佳临床实践,简要展望了ARDS研究的前沿趋势,并以专家对该主题的意见结束。正在进行的数字革命将有助于个性化ARDS治疗,因此可能会提高生存率和生活质量。
{"title":"Novel approaches that promote lung endothelial and epithelial repair and anti pro inflammatory cytokines could be a future promising agent in the management of ARDS","authors":"Montaser Alrjoob ,&nbsp;Alaa Alkhatib ,&nbsp;Rana Padappayil ,&nbsp;Husam Bader ,&nbsp;Doantrang Du ,&nbsp;Chandler Patton","doi":"10.1016/j.clicom.2023.07.005","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.07.005","url":null,"abstract":"<div><p>The acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in critically ill patients and is defined by the acute onset of noncardiogenic pulmonary edema, hypoxemia, and the need for mechanical ventilation. ARDS occurs most often in the setting of pneumonia, sepsis, aspiration of gastric contents or severe trauma, and is present in ∼10% of all intensive care unit patients worldwide. Pathologic specimens from patients with ARDS most frequently reveal diffuse alveolar damage, and laboratory studies have demonstrated both alveolar epithelial and lung endothelial injury, resulting in accumulation of protein-rich inflammatory edema fluid in the alveolar space. The current therapeutic regimen is comprised of supportive measures such as lung protective ventilation, restrictive fluid management, paralyzing drugs, and prone positioning. Although vast improvements have been made in ARDS-treatment during the last five decades, mortality among patients with severe ARDS remains at an unacceptable rate of 45%.This article reviews the evolution of the currently used definition, established pathophysiological mechanism, highlights the current best clinical practice to treat ARDS, gives a brief outlook on cutting edge trends in ARDS research and closes with an expert opinion on the subject. The ongoing digital revolution will help to individualize ARDS-treatment and will therefore presumably improve survival and quality of life.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49753027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum immunoglobulin levels and risk of antibiotic prescription in middle-aged and older individuals: A population-based cohort study 中老年个体血清免疫球蛋白水平和抗生素处方风险:一项基于人群的队列研究
Pub Date : 2023-07-22 DOI: 10.1016/j.clicom.2023.07.003
Anna Vanoverschelde , Samer R. Khan , Virgil A.S.H. Dalm , Layal Chaker , Guy Brusselle , Bruno H. Stricker , Lies Lahousse

Objectives

Elderly become more susceptible to lower respiratory tract infections, resulting in antibiotic prescriptions. Immunoglobulins (Ig) play an important role in host defense and protection against infections. Therefore, we aimed to investigate whether lower Ig levels are a risk factor for antibiotic use in the general elderly population.

Methods

After exclusion of current antibiotic users, Cox proportional-hazards regression models were performed to investigate the effect of stable serum IgM, IgG and IgA levels on time to first antibiotic prescription within the Rotterdam Study. Regression models were adjusted for age, sex, body mass index, smoking status and diabetes. We introduced quadratic terms and additionally categorized Igs to explore and quantify potential non-linearity of the association. The restricted cubic splines technique was used to plot the natural log of the hazard across Ig level.

Results

In total, 8,639 participants were included (mean age 64 years, 57% female, medium follow-up 3.2 years). No significant association between IgM and time to antibiotic prescription was observed. IgG and IgA levels (in g/L) showed a U-shaped relationship with time to antibiotic prescription (linear IgG HR 0.959, 95% CI 0.930–0.989; quadratic IgG² HR 1.002, 95% CI 1.000–1.003; linear IgA HR 0.949, 95% CI 0.910–0.990; quadratic IgA² HR 1.009, 95% CI 1.004–1.013).

Conclusion

Both low and high IgG and IgA levels were associated with a higher incidence of antibiotic prescriptions in stable middle-aged and older individuals. Increased awareness for the potential increased infection risk when persons have low or high Ig levels, even within the reference ranges, is needed.

目的老年人更容易感染下呼吸道,因此需要开具抗生素处方。免疫球蛋白(Ig)在宿主防御和预防感染方面发挥着重要作用。因此,我们旨在调查较低的Ig水平是否是普通老年人群使用抗生素的风险因素。方法在排除现有抗生素使用者后,采用Cox比例风险回归模型,研究鹿特丹研究中稳定的血清IgM、IgG和IgA水平对首次开具抗生素处方时间的影响。回归模型根据年龄、性别、体重指数、吸烟状况和糖尿病进行了调整。我们引入了二次项,并对Ig进行了额外的分类,以探索和量化关联的潜在非线性。使用限制性三次样条技术绘制Ig水平下危害的自然对数。结果共有8639名参与者(平均年龄64岁,57%为女性,中期随访3.2年)。IgM与抗生素处方时间之间没有显著相关性。IgG和IgA水平(g/L)与抗生素处方时间呈U型关系(线性IgG HR 0.959,95%CI 0.930–0.989;二次型IgG²HR 1.002,95%CI 1.000–1.003;线性IgA HR 0.949,95%CI 0.910–0.990;二次性IgA²HR 1.009,95%CI 1.004–1.013)稳定的中老年人。当人们的Ig水平低或高时,即使在参考范围内,也需要提高对潜在感染风险增加的认识。
{"title":"Serum immunoglobulin levels and risk of antibiotic prescription in middle-aged and older individuals: A population-based cohort study","authors":"Anna Vanoverschelde ,&nbsp;Samer R. Khan ,&nbsp;Virgil A.S.H. Dalm ,&nbsp;Layal Chaker ,&nbsp;Guy Brusselle ,&nbsp;Bruno H. Stricker ,&nbsp;Lies Lahousse","doi":"10.1016/j.clicom.2023.07.003","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.07.003","url":null,"abstract":"<div><h3>Objectives</h3><p>Elderly become more susceptible to lower respiratory tract infections, resulting in antibiotic prescriptions. Immunoglobulins (Ig) play an important role in host defense and protection against infections. Therefore, we aimed to investigate whether lower Ig levels are a risk factor for antibiotic use in the general elderly population.</p></div><div><h3>Methods</h3><p>After exclusion of current antibiotic users, Cox proportional-hazards regression models were performed to investigate the effect of stable serum IgM, IgG and IgA levels on time to first antibiotic prescription within the Rotterdam Study. Regression models were adjusted for age, sex, body mass index, smoking status and diabetes. We introduced quadratic terms and additionally categorized Igs to explore and quantify potential non-linearity of the association. The restricted cubic splines technique was used to plot the natural log of the hazard across Ig level.</p></div><div><h3>Results</h3><p>In total, 8,639 participants were included (mean age 64 years, 57% female, medium follow-up 3.2 years). No significant association between IgM and time to antibiotic prescription was observed. IgG and IgA levels (in g/L) showed a U-shaped relationship with time to antibiotic prescription (linear IgG HR 0.959, 95% CI 0.930–0.989; quadratic IgG² HR 1.002, 95% CI 1.000–1.003; linear IgA HR 0.949, 95% CI 0.910–0.990; quadratic IgA² HR 1.009, 95% CI 1.004–1.013).</p></div><div><h3>Conclusion</h3><p>Both low and high IgG and IgA levels were associated with a higher incidence of antibiotic prescriptions in stable middle-aged and older individuals. Increased awareness for the potential increased infection risk when persons have low or high Ig levels, even within the reference ranges, is needed.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49752593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Immunology Communications
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1